View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2021updated 12 Jul 2022 11:06am

Appili to conduct Covid-19 treatment trial in Mexico and Brazil

Site activation is underway in Mexico while the process is anticipated to commence soon in Brazil. 

Appili Therapeutics has expanded the Phase III clinical trial of Avigan/Reeqonus (favipiravir) with the addition of multiple clinical research centres in Mexico and Brazil to treat mild to moderate Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed by FUJIFILM Toyama Chemical, Avigan is a broad-spectrum oral antiviral approved in Japan for influenza treatment.

The drug selectively hinders viral ribonucleic acid (RNA)-dependent RNA polymerase (RdRP) with strong antiviral activity against single-stranded RNA viruses, such as coronaviruses.

Named PRESECO, the Phase III trial is assessing the safety and efficacy of Avigan as a home-based treatment option for mild-to-moderate Covid-19.

The primary aim of the trial is a substantial reduction in time to a sustained recovery in participants who receive Avigan versus placebo.

More than 730 subjects have so far been enrolled in the US trial, which initiated dosing in December last year.

Appili noted that the latest expansion into Mexico and Brazil will aid in concluding the trial on time and establish favipiravir as an oral Covid-19 antiviral candidate.

Site activation is progressing in Mexico while some centres are open and currently enrolling study participants. In Brazil, site activation is anticipated to commence soon.

Top-line data from the Phase III trial is expected to be available in September this year.

Appili Therapeutics chief medical officer Yoav Golan said: “With cases decreasing in the US our clinical expansion into Brazil and Mexico will help us meet our enrolment goal.

“With this expansion of our trial, we will be able to move quicker towards our goal of determining whether Avigan/Reeqonus is effective in helping people who suffer from mild-to-moderate Covid-19 to recover faster and avoid hospitalisation and death.”

An independent Data and Safety Monitoring Board recently advised continuing the PRESECO study without any changes.

As part of this trial expansion, Appili has stopped its Phase II CONTROL trial of Avigan for Covid-19 treatment in long-term care settings.

Furthermore, Appili intends to launch a Phase III PEPCO study of Avigan to prevent Covid-19 in asymptomatic people who were directly exposed to an infected individual.

The company expects to start enrolment in PEPCO study in the second half of this year, after concluding PRESECO.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena